This angiotensin-converting enzyme inhibitor and this blood pressure-lowering agent contain a compound represented by formula (I) as an active ingredient. These beverages and food products for inhibiting an angiotensin-converting enzyme and these beverages and food products for lowering blood pressure are characterized by containing a compound represented by formula (I). As a result, provided are an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent that have an excellent angiotensin-converting enzyme-inhibiting effect and blood pressure-lowering effect. Furthermore, provided are beverages and food products suitable for inhibition of an angiotensin-converting enzyme and lowering of blood pressure.

##STR00001##

A nutrient selected from the group consisting of beta-carotene, fiber, Vitamin C, Folate, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12 and Potassium, or combination of two of more thereof, for use in treating or preventing mastitis, especially subclinical mastitis, in a subject.

A nutrient selected from the group consisting of beta-carotene, fiber, Vitamin C, Folate, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12 and Potassium, or combination of two of more thereof, for use in treating or preventing mastitis, especially subclinical mastitis, in a subject.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands. The method of administering the composition of the present invention consisting essentially of omega-3 fatty acids may further comprise (1) the steps of taking a baseline measurement of tear break up time of the mammal prior to administering the composition and taking a second measurement of tear break up time of the treated mammal after administration of the composition to evaluate the improvement in tear break up time of the mammal as compared to the corresponding baseline measurement, (2) the steps of taking a baseline measurement of tear osmolarity of the mammal prior to administering the composition and taking a second measurement of tear osmolarity of the mammal after administration of the composition to evaluate the reduction of tear osmolarity of the mammal as compared to the corresponding baseline measurement and/or (3) the steps of taking a baseline measurement of the quality of tears of the mammal prior to administering the composition and taking a second measurement of the quality of tears of the mammal after administration of the composition to evaluate the improvement in the quality of tears of the mammal as compared to the corresponding baseline measurement.

Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.

Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.

The present invention relates to the use of a combination of a yeast of the species Saccharomyces cerevisiae, resveratrol and a curcuma extract, for use in the management of a subject who has endometriosis or is susceptible to endometriosis. The combination according to the invention may be used in the treatment or prevention of endometriotic lesions in a subject who has endometriosis or is susceptible to endometriosis, for example to slow the development or to reduce the endometriotic lesions. It may also be used in the treatment or prevention of one or more symptoms or disorders associated with endometriosis. The invention also relates to pharmaceutical or nutraceutical compositions and kits based on said combination.

The present invention relates to the use of a combination of a yeast of the species Saccharomyces cerevisiae, resveratrol and a curcuma extract, for use in the management of a subject who has endometriosis or is susceptible to endometriosis. The combination according to the invention may be used in the treatment or prevention of endometriotic lesions in a subject who has endometriosis or is susceptible to endometriosis, for example to slow the development or to reduce the endometriotic lesions. It may also be used in the treatment or prevention of one or more symptoms or disorders associated with endometriosis. The invention also relates to pharmaceutical or nutraceutical compositions and kits based on said combination.

The present invention provides a method of reducing uric acid in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of fucoxanthin, wherein the fucoxanthin has the effect of reducing uric acid and preventing gout.